Biotage AB appointment of new CEO

15-Aug-2024
Computer-generated image

Symbolic image

BiotageAB announced the appointment of Frederic Vanderhaegen as chief executive officer, effective September 16th 2024. Mr. Vanderhaegen succeeds Torben Jørgensen, who stepped in as interim CEO in January 2024 and he will now continue as a board member.

Frederic Vanderhaegen is a prominent life science leader with 30+ years’ experience leading complex organisations with portfolios including laboratory products, diagnostics, and medical devices. He is ideally positioned to lead the company through its next ambitious phase of growth.

Frederic joins Biotage from Avantor where he was General Manager and Executive Vice President for Europe. He also led the global portfolio for the life science business, sourcing and commercial excellence teams. Prior to Avantor, he worked for Ortho Clinical Diagnostics, Danaher, Tecan and Millipore in various senior leadership positions.

Frederic holds a Biochemical Engineering degree from Haute Ecole Lucia Debroeckere, a Chemical and Agricultural Engineering degree from Universite Libre de Bruxelles and an MBA from the Open University.

Other news from the department business & finance

Most read news

More news from our other portals